CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $25.52M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.45: distress zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
308.79MUSDvs all stocks (USD)
Revenue (TTM)
25.52MUSDvs all stocks (USD)
Profit Margin
-246.42%vs Biotechnology peers
Beta
1.32xvs all stocks
52-Week Change
1.31%vs all stocks
Market Capitalization
308.79MUSDvs all stocks (USD)
Enterprise Value
183.56MUSDvs all stocks (USD)
Forward P/E
-155.14xvs Biotechnology peers
Price to Sales (TTM)
12.17xvs Biotechnology peers
Price to Book (MRQ)
2.43xvs Biotechnology peers
Enterprise to Revenue
7.19xvs Biotechnology peers
Enterprise to EBITDA
-2.27xvs Biotechnology peers
Gross Margin
63.30%vs Biotechnology peers
Profit Margin
-246.42%vs Biotechnology peers
Operating Margin
-119.97%vs Biotechnology peers
Return on Assets (TTM)
-24.55%vs Biotechnology peers
Return on Equity (TTM)
-43.13%vs Biotechnology peers
Revenue (TTM)
25.52MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4570USDUpdated Sep 26, 2026Quarterly Revenue Growth
2745.00%vs Biotechnology peers
Gross Profit (TTM)
-10.18MUSDvs all stocks (USD)
EBITDA (TTM)
72.45MUSDvs all stocks (USD)
Net Income (TTM)
-62.89MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2745.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-76.44MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-73.40MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
5.82MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
3.42MUSDFY2025 · Dec 31, 2025Gross Profit
2.40MUSDFY2025 · Dec 31, 2025Operating Income
-89.45MUSDvs all stocks (USD)
Pre-tax Income
71.28MUSDFY2025 · Dec 31, 2025Income Tax Expense
100.00KUSDFY2025 · Dec 31, 2025Net Income
71.18MUSDFY2025 · Dec 31, 2025EBIT
75.02MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.45MUSDFY2025 · Dec 31, 2025Research & Development
26.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.74MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.34USDFY2025 · Dec 31, 2025EPS (Diluted)
1.01USDFY2025 · Dec 31, 2025Basic Shares Outstanding
52.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
52.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
71.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
82.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
82.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 3.56M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -84.3M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.44MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
2.59MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
71.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.78MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.04MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.54MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.84MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-206.63MUSDFY2025 · Dec 31, 2025Sale of Investments
167.27MUSDFY2025 · Dec 31, 2025Other Investing Activity
152.37MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
113.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-37.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.26MUSDFY2025 · Dec 31, 2025Shares Outstanding
57.23MSharesUpdated Sep 26, 2026Float Shares
36.81MSharesUpdated Sep 26, 2026Shares Short
15.75MSharesUpdated Sep 26, 2026Short Ratio
12.95daysvs all stocks
Short % of Shares Outstanding
29.55%vs all stocks
% Held by Insiders
11.31%vs all stocks
% Held by Institutions
74.89%vs all stocks
Total Cash (MRQ)
146.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.57USDUpdated Sep 26, 2026Total Debt (MRQ)
19.87MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1552xvs Biotechnology peers
Current Ratio (MRQ)
6.63xvs Biotechnology peers
Book Value per Share (MRQ)
2.24USDUpdated Sep 26, 2026Total Assets
219.57MUSDvs all stocks (USD)
Total Current Assets
204.91MUSDFY2025 · Dec 31, 2025Total Liabilities
60.35MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.66MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.78MUSDFY2025 · Dec 31, 2025Total Current Liabilities
29.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
78.44MUSDFY2025 · Dec 31, 2025Other Short-term Investments
112.97MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.15MUSDFY2025 · Dec 31, 2025Inventory
5.49MUSDFY2025 · Dec 31, 2025Accounts Payable
7.89MUSDFY2025 · Dec 31, 2025Short-term Debt
13.09MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.00KUSDFY2025 · Dec 31, 2025Long-term Debt
11.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
550.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-742.08MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
159.22MUSDvs all stocks (USD)
52-Week Low
4.00USDUpdated Sep 26, 202652-Week High
7.65USDUpdated Sep 26, 202652-Week Change
1.31%vs all stocks
Beta
1.32xvs all stocks
50-Day MA
6.17USDUpdated Sep 26, 2026200-Day MA
5.55USDUpdated Sep 26, 2026Avg 10-Day Volume
1.72MSharesUpdated Sep 26, 2026Avg 30-Day Volume
1.60MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-1.21USDUpdated Sep 26, 2026Other Income / Expense
158.91MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: -2.46
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.63Altman Z-Score: 0.45
Financial Health
Altman Z-Score 0.45: distress zoneCritical
Altman Z-Score: 0.45
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $25.52M, lower than 95% of all stocks globallySignificant
Revenue (USD): 25,520,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Saint Bella Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Sun Corporation
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)
5 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios Elevated